Cartesian Therapeutics Inc. (RNAC)
NASDAQ: RNACHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RNAC stock chart
Technical analysisKey statistics
All statistics- Market cap
- $187.29M
- EPS (TTM)
- -$4.78
- Dividend yield
- None
- 52-week range
- 5.60 – 11.00
- Day range
- 5.89 – 6.32
- Volume / Avg
- 279.31K / 139.65K
- Beta
- —
- Shares outstanding
- 30.50M
52-week range
RNAC stock today
Cartesian Therapeutics (RNAC) closed at $6.14 on Nov 20, up 4.24% (+$0.25), versus the S&P 500's 3.70% decline. Volume was 2.0x the average at 279.31K shares, a sign of unusually heavy trading. At this level, RNAC sits near the bottom of its 52-week range of $5.60 to $11.00: 44.2% below the high, set on Jun 24, 2026 and 9.6% above the low.
RNAC is down 14.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 15.2%. Cartesian Therapeutics has posted a net loss over the last twelve months (EPS of -$4.78), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Cartesian Therapeutics
Company profileCartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous B cell maturation antigen (BCMA) that is in phase 1 trials directed mRNA CAR-T to treat patients with multiple myeloma.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Carsten Brunn Ph.D.
- Headquarters
- Frederick, MD
- Employees
- 75
- IPO year
- 2016
- Website
- cartesiantherapeutics.com
Financial highlights
Full financialsIn fiscal 2025, Cartesian Therapeutics generated $2.8 million in revenue, down 92.8% from fiscal 2024, its first annual decline since 2023. Cartesian Therapeutics reported a net loss of $130.3 million, compared with a loss of $77.4 million a year earlier. Operating margin was -5127.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $2.80M | $38.91M | $26.00M | $110.78M | $85.08M |
| Growth | -92.81% | +49.64% | -76.53% | +30.21% | +412.60% |
| Net income | $-130.30M | $-77.42M | $-219.71M | $35.38M | $-25.69M |
| EPS (diluted) | $-5.02 | $-4.49 | $-49.76 | $0.10 | $-0.22 |
Analyst forecast
ForecastConsensus (7 analysts)
strong_buy
Avg. price target
$33.67+448.37%
- Strong buy 1
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.38 vs $-1.02
- Surprise
- +62.75%
RNAC news
All RNAC newsCartesian Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ANTXAN2 Therapeutics Inc. | 5.08 | -2.68% | $192.75M | vs RNAC |
| WHWKWhitehawk Therapeutics Inc. | 3.07 | -1.60% | $181.16M | vs RNAC |
| ACIUAC Immune SA | 1.95 | -8.45% | $193.88M | vs RNAC |
| SLGLSol-Gel Technologies Ltd. | 55.17 | +2.02% | $180.63M | vs RNAC |
| ADCTADC Therapeutics SA | 1.28 | -1.54% | $180.05M | vs RNAC |
| YARWYarrow Bioscience Inc. | 12.90 | -9.35% | $196.53M | vs RNAC |
| BIOABioAge Labs Inc. | 4.28 | -9.13% | $196.67M | vs RNAC |
| NATRNature's Sunshine Products Inc. | 10.18 | +0.10% | $176.41M | vs RNAC |
Indexes, lists and sector
Cartesian Therapeutics stock FAQ
What is Cartesian Therapeutics's stock price today?
RNAC last traded at $6.14 as of Nov 20, 4:00 PM EST, up 4.24% on the day. Prices are delayed at least 15 minutes.
Does Cartesian Therapeutics pay a dividend?
No. Cartesian Therapeutics does not currently pay a regular cash dividend.
Who is Cartesian Therapeutics's CEO?
Dr. Carsten Brunn Ph.D. is the chief executive officer of Cartesian Therapeutics Inc., which has about 75 employees.
Has RNAC ever split its stock?
Yes. The most recent RNAC stock split was a 1-for-30 split on Apr 5, 2024.
What is the RNAC 52-week high?
The 52-week high for RNAC is $11.00 and the 52-week low is $5.60. The stock is currently 44.2% below its high.